Artificial Intelligence (AI) has advanced tremendously and today promises personalized healthcare; enhanced national security; improved transportation; and more effective education, to name just a few benefits. Increased computing power, the availability of large datasets and streaming data, and algorithmic advances in machine learning (ML) have made it possible for AI development to create new sectors of the economy and revitalize industries. Continued advancement, enabled by sustained federal investment and channeled toward issues of national importance, holds the potential for further economic impact and quality-of-life improvements.
This Funding Opportunity Announcement (FOA) invites applications for research and development to improve functioning and quality of life for the elderly, especially the disabled elderly, living in low- and middle-income countries (LMICs), or to improve functioning and quality of life for low-income, disabled, and isolated elderly living in high-income countries. Applications may address the needs of the elderly directly or indirectly by supporting family or other informal caregivers and service providers. Applications likely to have an impact on a large scale are encouraged.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic science and preclinical research to determine the biological mechanisms underlying the effects of cannabinoids and the endocannabinoid system on HIV-associated persistent inflammation and its consequent effects on nervous system function. Projects submitted in response to this FOA must include expertise and resources in both areas of HIV/AIDS and addiction science.
The purpose of this NOFO is to support a mechanism to obtain timely input from nationally representative samples of (a) healthcare providers and (b) the public on critical immunization issues of importance. The objectives of this research are (1) for each year of the project, to conduct multiple surveys of providers and the public to collect immunization-related data using scientifically sound methods with adequate response rates that produce generalizable results, and (2) to disseminate those results broadly to assist in (a) informing recommendations for new vaccines, (b) developing strategies to improve immunization coverage, and (c) instituting contingency plans to address urgent problems (e.g., vaccine supply shortages). Surveyed providers should include pediatricians, family physicians, obstetrician/gynecologists, general internists, or some combination of these physician specialties. Surveyed members of the public should be ≥18 years old and should include subpopulations of special interest for consideration of immunization-related issues such as pregnant women, parents of children aged 0 to 5 years, and persons with chronic medical conditions.
The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).
The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), Division of Cardiovascular and Renal Products (DCRP) is announcing its intent to accept and consider applications for the award of a grant to support the Heart Failure Collaboratory
The purpose of this FOA is to solicit applications for research projects to generate reference datasets and to create navigable maps for the study of the spatial and temporal organization of the nucleus, using genomic and imaging data as well as newly developed visualization and integrative analysis tools.
The purpose of the initiative is to support multidisciplinary innovative exploratory and developmental research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US.
Also listed under R01.
The Foundation encourages submission of applications from Academy Members that explore lifestyle interventions which can reduce the risk of development of childhood overweight and obesity by focusing on nutrition and physical activity.
The INSPIRE awards program was established to address some of the most complicated and pressing scientific problems that lie at the intersection of traditional disciplines. It is intended to encourage investigators to submit bold, exceptional proposals that some may consider to be at a disadvantage in a standard NSF review process; it is not intended for proposals that are more appropriate for existing award mechanisms.
NOTICE: Applications are submitted to the American Heart Association via Grants@Heart, a Web-based application system. Grants@Heart is scheduled to open on May 15, 2013. In the meantime, please review the program listings, instructions and information in preparation for your application.
This FOA invites applications that apply a cross-disciplinary, team science approach to gain comprehensive, mechanistic understanding of the impact of sex differences on the trajectories of brain aging and phenotypes of AD risk and on the responsiveness to pharmacologic and non-pharmacologic interventions.
The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes. Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.
A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. While currently available technologies can provide some understanding, they may not be sufficient to accomplish this goal. For example, non-invasive technologies are low resolution and/or provide indirect measures such as blood flow, which are imprecise; invasive technologies can provide information at the level of single neurons producing the fundamental biophysical signals, but they can only be applied to tens or hundreds of neurons, out of a total number in the human brain estimated at 85 billion.
Other BRAIN FOAs seek to develop novel technology (RFA-NS-16-006) or to optimize existing technology ready for in-vivo proof-of-concept testing and collection of preliminary data (RFA-NS-16-007) for recording or manipulating neural activity on a scale that is beyond what is currently possible. This FOA seeks applications for unique and innovative technologies that are in an even earlier stage of development than that sought in other FOAs, including new and untested ideas that are in the initial stages of conceptualization.
This Request for Proposal (RFP) seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging. More accurate and comprehensive biomarkers will improve patient selection and pharmacodynamic measurements, and provide additional tools for early detection and accurate diagnosis.
This Funding Opportunity Announcement (FOA) will support rigorous, pre-clinical studies that establish the rationale for a clinical trial, where the hypothesis originates from use of a published or publicly available method for identifying new indications for existing drugs or biologics (therapeutics). The goal of an individual project will be to explore the potential new use of an existing investigational, phase 2a-ready, or FDA-approved drug or licensed biologic; a pre-clinical study funded through this initiative will serve as a use case to demonstrate the utility of an independent crowdsourcing effort or of a computational algorithm to predict new uses of a drug or biologic.
The intention of this Funding Opportunity Announcement is to improve the prevention, diagnosis, and treatment of vulvodynia. By definition, vulvar discomfort or pain without a clear etiology is termed vulvodynia. Some organizations use the term vulvodynia to indicate vulvar pain of unknown etiology for more than 3 months. For the purposes of this announcement, vulvodynia and vulvar pain will be used interchangeably. The overall incidence of vulvodynia has been reported as 4.2 cases per 100 person-years in one population based study, with others estimating that persistent vulvar pain affects 9 to 18 percent of women at some point during their lifetime. Current evidence suggests that incidence rates vary by age, ethnicity and marital status.
This Funding Opportunity Announcement (FOA) encourages applications that propose to evaluate policies or large scale programs that are expected to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes have the potential to prevent or reduce rates of obesity.
The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism.
The purpose of this funding opportunity announcement (FOA) is to encourage modular budget R01 grant applications from nurse scientists who are currently or were recently supported by an NIH Career Development (K) award. This opportunity is limited to those K awardee nurse scientists who have not yet earned an R01 equivalent award. Through this opportunity, NINR seeks to enhance the transition of nurse scientists to independent investigator status.
